Phosphorylated akt and phosphorylated mtor expression in breast invasive carcinomas

Analysis of 530 cases

Jungsuk An, Hoiseon Jeong, Youngseok Lee, Sang- Uk Woo, Jae Hong Seo, Aeree Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: The phosphatidylinositol 3-kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR) pathway has a central role in regulation of cell proliferation, differentiation, motility and survival. This pathway has recently generated great interest because its elements are, potentially, novel targets for the treatment of various malignancies, including breast cancer. Methods: Using tissue microarray sections of breast carcinoma, we performed immunohistochemical studies using antibodies against the phosphorylated forms of Akt (p-Akt) and mTOR (p-mTOR) in 530 invasive breast carcinomas and 30 ductal carcinomas in situ (DCIS). We investigated possible associations between expression of these proteins and clinicopathologic characteristics and disease outcomes. Results: In 530 invasive carcinomas, weak and strong expression of p-Akt was observed in 180 (34.0%) and 288 (54.3%) cases, respectively. The expression of p-Akt was associated with expression of estrogen receptors (ER) (p=0.045), progesterone receptors (PR) (p=0.003), lymph node metastasis (p<0.001) and cancer stage (p=0.027). Weak and strong expression of p-mTOR was found in 136 (25.7%) and 207 (39.1%) cases, respectively. The mTOR pathway was more frequently activated in DCIS than in invasive breast carcinoma (p=0.001). p-mTOR expression was associated with expression of ER (p=0.040), PR (p=0.009), tumor size (p<0.001), and stage (p=0.002). In a univariate analysis, strong expression of p-Akt was associated with longer disease-free survival (DFS). In a multivariate analysis, neither p-Akt nor p-mTOR was associated with DFS. Conclusion: The PI3K/Akt/mTOR pathway is active in DCIS as well as in invasive carcinoma of the breast. Our study also suggests that the PI3K/Akt/mTOR pathway is influenced by ER rather than erbB-2, and that this pathway may contribute more to cancer pathogenesis in ER-positive tumors.

Original languageEnglish
Pages (from-to)337-348
Number of pages12
JournalJournal of Breast Cancer
Volume13
Issue number4
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Sirolimus
Phosphatidylinositol 3-Kinase
Estrogen Receptors
Carcinoma, Intraductal, Noninfiltrating
Breast Neoplasms
Progesterone Receptors
Neoplasms
Disease-Free Survival
Cell Differentiation
Cell Survival
Multivariate Analysis
Lymph Nodes
Cell Proliferation
Neoplasm Metastasis
Carcinoma
Antibodies
Proteins

Keywords

  • Breast
  • Carcinoma
  • mTOR protein
  • Proto-oncogene protein c-akt

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phosphorylated akt and phosphorylated mtor expression in breast invasive carcinomas : Analysis of 530 cases. / An, Jungsuk; Jeong, Hoiseon; Lee, Youngseok; Woo, Sang- Uk; Seo, Jae Hong; Kim, Aeree.

In: Journal of Breast Cancer, Vol. 13, No. 4, 01.12.2010, p. 337-348.

Research output: Contribution to journalArticle

@article{f624595ea2c049a398b0a97ab08e4548,
title = "Phosphorylated akt and phosphorylated mtor expression in breast invasive carcinomas: Analysis of 530 cases",
abstract = "Purpose: The phosphatidylinositol 3-kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR) pathway has a central role in regulation of cell proliferation, differentiation, motility and survival. This pathway has recently generated great interest because its elements are, potentially, novel targets for the treatment of various malignancies, including breast cancer. Methods: Using tissue microarray sections of breast carcinoma, we performed immunohistochemical studies using antibodies against the phosphorylated forms of Akt (p-Akt) and mTOR (p-mTOR) in 530 invasive breast carcinomas and 30 ductal carcinomas in situ (DCIS). We investigated possible associations between expression of these proteins and clinicopathologic characteristics and disease outcomes. Results: In 530 invasive carcinomas, weak and strong expression of p-Akt was observed in 180 (34.0{\%}) and 288 (54.3{\%}) cases, respectively. The expression of p-Akt was associated with expression of estrogen receptors (ER) (p=0.045), progesterone receptors (PR) (p=0.003), lymph node metastasis (p<0.001) and cancer stage (p=0.027). Weak and strong expression of p-mTOR was found in 136 (25.7{\%}) and 207 (39.1{\%}) cases, respectively. The mTOR pathway was more frequently activated in DCIS than in invasive breast carcinoma (p=0.001). p-mTOR expression was associated with expression of ER (p=0.040), PR (p=0.009), tumor size (p<0.001), and stage (p=0.002). In a univariate analysis, strong expression of p-Akt was associated with longer disease-free survival (DFS). In a multivariate analysis, neither p-Akt nor p-mTOR was associated with DFS. Conclusion: The PI3K/Akt/mTOR pathway is active in DCIS as well as in invasive carcinoma of the breast. Our study also suggests that the PI3K/Akt/mTOR pathway is influenced by ER rather than erbB-2, and that this pathway may contribute more to cancer pathogenesis in ER-positive tumors.",
keywords = "Breast, Carcinoma, mTOR protein, Proto-oncogene protein c-akt",
author = "Jungsuk An and Hoiseon Jeong and Youngseok Lee and Woo, {Sang- Uk} and Seo, {Jae Hong} and Aeree Kim",
year = "2010",
month = "12",
day = "1",
doi = "10.4048/jbc.2010.13.4.337",
language = "English",
volume = "13",
pages = "337--348",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "4",

}

TY - JOUR

T1 - Phosphorylated akt and phosphorylated mtor expression in breast invasive carcinomas

T2 - Analysis of 530 cases

AU - An, Jungsuk

AU - Jeong, Hoiseon

AU - Lee, Youngseok

AU - Woo, Sang- Uk

AU - Seo, Jae Hong

AU - Kim, Aeree

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Purpose: The phosphatidylinositol 3-kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR) pathway has a central role in regulation of cell proliferation, differentiation, motility and survival. This pathway has recently generated great interest because its elements are, potentially, novel targets for the treatment of various malignancies, including breast cancer. Methods: Using tissue microarray sections of breast carcinoma, we performed immunohistochemical studies using antibodies against the phosphorylated forms of Akt (p-Akt) and mTOR (p-mTOR) in 530 invasive breast carcinomas and 30 ductal carcinomas in situ (DCIS). We investigated possible associations between expression of these proteins and clinicopathologic characteristics and disease outcomes. Results: In 530 invasive carcinomas, weak and strong expression of p-Akt was observed in 180 (34.0%) and 288 (54.3%) cases, respectively. The expression of p-Akt was associated with expression of estrogen receptors (ER) (p=0.045), progesterone receptors (PR) (p=0.003), lymph node metastasis (p<0.001) and cancer stage (p=0.027). Weak and strong expression of p-mTOR was found in 136 (25.7%) and 207 (39.1%) cases, respectively. The mTOR pathway was more frequently activated in DCIS than in invasive breast carcinoma (p=0.001). p-mTOR expression was associated with expression of ER (p=0.040), PR (p=0.009), tumor size (p<0.001), and stage (p=0.002). In a univariate analysis, strong expression of p-Akt was associated with longer disease-free survival (DFS). In a multivariate analysis, neither p-Akt nor p-mTOR was associated with DFS. Conclusion: The PI3K/Akt/mTOR pathway is active in DCIS as well as in invasive carcinoma of the breast. Our study also suggests that the PI3K/Akt/mTOR pathway is influenced by ER rather than erbB-2, and that this pathway may contribute more to cancer pathogenesis in ER-positive tumors.

AB - Purpose: The phosphatidylinositol 3-kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR) pathway has a central role in regulation of cell proliferation, differentiation, motility and survival. This pathway has recently generated great interest because its elements are, potentially, novel targets for the treatment of various malignancies, including breast cancer. Methods: Using tissue microarray sections of breast carcinoma, we performed immunohistochemical studies using antibodies against the phosphorylated forms of Akt (p-Akt) and mTOR (p-mTOR) in 530 invasive breast carcinomas and 30 ductal carcinomas in situ (DCIS). We investigated possible associations between expression of these proteins and clinicopathologic characteristics and disease outcomes. Results: In 530 invasive carcinomas, weak and strong expression of p-Akt was observed in 180 (34.0%) and 288 (54.3%) cases, respectively. The expression of p-Akt was associated with expression of estrogen receptors (ER) (p=0.045), progesterone receptors (PR) (p=0.003), lymph node metastasis (p<0.001) and cancer stage (p=0.027). Weak and strong expression of p-mTOR was found in 136 (25.7%) and 207 (39.1%) cases, respectively. The mTOR pathway was more frequently activated in DCIS than in invasive breast carcinoma (p=0.001). p-mTOR expression was associated with expression of ER (p=0.040), PR (p=0.009), tumor size (p<0.001), and stage (p=0.002). In a univariate analysis, strong expression of p-Akt was associated with longer disease-free survival (DFS). In a multivariate analysis, neither p-Akt nor p-mTOR was associated with DFS. Conclusion: The PI3K/Akt/mTOR pathway is active in DCIS as well as in invasive carcinoma of the breast. Our study also suggests that the PI3K/Akt/mTOR pathway is influenced by ER rather than erbB-2, and that this pathway may contribute more to cancer pathogenesis in ER-positive tumors.

KW - Breast

KW - Carcinoma

KW - mTOR protein

KW - Proto-oncogene protein c-akt

UR - http://www.scopus.com/inward/record.url?scp=79251486345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251486345&partnerID=8YFLogxK

U2 - 10.4048/jbc.2010.13.4.337

DO - 10.4048/jbc.2010.13.4.337

M3 - Article

VL - 13

SP - 337

EP - 348

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 4

ER -